TP63 is a p53 family member that functions as a sequence-specific DNA-binding transcriptional regulator with isoform-dependent activities 1. The gene produces multiple isoforms: transactivation-domain-containing (TA) isoforms that resemble p53 in activating transcription and inducing cell cycle arrest and apoptosis, and delta-N (ΔN) isoforms that lack transactivation domains and function as dominant-negative inhibitors 1. ΔNp63α, the predominant isoform in epithelial tissues, acts as a pioneer factor that orchestrates chr3 remodeling and enhancer reprogramming to establish tissue-specific gene expression patterns 2. Unlike TP53, TP63 is rarely inactivated in cancer but frequently amplified (~25%) in squamous cell carcinomas, with ΔN isoforms promoting oncogenesis through enhancer-driven activation of oncogenic targets including MYC 32. TP63 fusions in lymphomas act as bona fide oncogenes, recruiting epigenetic complexes (NCoR-HDAC3, KMT2D) to create therapeutic vulnerabilities, notably EZH2 dependence 4. Developmentally, TP63 is essential for epithelial morphogenesis, limb formation, and maintaining stem cell compartments 1. Heterozygous TP63 mutations cause multiple developmental syndromes including ectrodactyly-ectodermal dysplasia-cleft palate (EEC), limb-mammary syndrome, and non-syndromic cleft lip 5. TA isoforms can induce chemosensitivity through p53-like mechanisms 3, while dysregulated expression underlies both developmental and oncogenic phenotypes.